Flecainide

Major

Flecainide Doxepin Prudoxin An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Droperidol An increased risk of QT interval prolongation Details Flecainide Duloxetine Increased class IC antiarrhythmic serum concentrations and an increased risk of cardiotoxicity (QT prolongation, torsades de point... Details Flecainide Efavirenz An increased risk of QT interval prolongation Details Flecainide Enflurane An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Epinephrine An increased risk of cardiac arrhythmias Details Flecainide Erythromycin Erythrocin Stearate Increased risk of QT interval prolongation Details Flecainide Escitalopram Lexapro An increased risk of QT interval prolongation and increased CYP2D6 substrate exposure Details Flecainide Etrasimod Velsipity Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Flecainide Etravirine Intelence Decreased flecainide plasma concentrations Details Flecainide Fedratinib Inrebic Increased CYP2D6 substrate exposure Details Flecainide Fexinidazole An increased risk of QT interval prolongation Details Flecainide Fingolimod Gilenya Increased risk of QT interval prolongation Details Flecainide Fluconazole Diflucan An increased risk of QT interval prolongation Details Flecainide Fluoxetine RECONCILE Increased flecainide exposure and an increased risk of QT interval prolongation Details Flecainide Formoterol Perforomist Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Flecainide Foscarnet Foscavir An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Fosfomycin Contepo An increased risk of QT interval prolongation Details Flecainide Fosphenytoin Cerebyx An increased risk of QT interval prolongation Details Flecainide Fostemsavir Rukobia Increased risk of torsade de pointes Details Flecainide Gatifloxacin Zymaxid An increased risk of QT interval prolongation Details Flecainide Gemifloxacin Factive An increased risk of QT interval prolongation Details Flecainide Gepirone Exxua An increased risk of QT interval prolongation and cardiac arrhythmias Details Flecainide Gepotidacin Blujepa An increased risk of QT interval prolongation Details Flecainide Givinostat Duvyzat Increased risk of QT interval prolongation and torsade de pointes Details Flecainide Glasdegib Daurismo Increased risk of QT interval prolongation Details Flecainide Goserelin Increased risk of QT interval prolongation Details Flecainide Granisetron An increased risk of QT interval prolongation Details Flecainide Halofantrine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Haloperidol Increased haloperidol exposure, an increased risk of haloperidol-related adverse events and an increased risk of QT interval prolo... Details Flecainide Halothane An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Histrelin Supprelin Increased risk of QT interval prolongation Details Flecainide Hydrochlorothiazide Inzirqo Increased risk of electrolyte imbalance and subsequent cardiotoxicity Details Flecainide Hydroflumethiazide Increased risk of electrolyte imbalance and subsequent cardiotoxicity Details Flecainide Hydroquinidine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Hydroxychloroquine Plaquenil Increased risk of QT interval prolongation Details Flecainide Hydroxyzine An increased risk of QT interval prolongation Details Flecainide Ibutilide Corvert An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Flecainide Iloperidone Fanapt An increased risk of QT interval prolongation Details Flecainide Imatinib Gleevec Increased CYP2D6 substrate exposure with NTI exposure and an increased risk of CYP2D6 substrates with NTI-related adverse reaction... Details